Oxidative stress and programmed death pathways: Cross talk in pancreatic cancer
Oxidative stress and programmed death pathways: Cross talk in pancreatic cancer
批准号:
8680146
负责人:
ADDANKI PRATAP KUMAR
金额:
$36.25万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-30 至 2017-06-30
关键词:
AddressAdverse effectsAnimal ModelApoptosisApoptoticAutophagocytosisBiochemicalBiologicalBiological FactorsCancer BiologyCancer Cell GrowthCancer PatientCancer cell lineCell Culture TechniquesCell DeathCell Death ProcessCell SurvivalCessation of lifeChinese HerbsCommunicable DiseasesDevelopmentDiagnosisDiseaseDown-RegulationDrug resistanceExclusionGeneticHerbal MedicineHumanIncidenceInduction of ApoptosisInflammationIntestinesMalignant NeoplasmsMalignant neoplasm of pancreasMediatingModelingMolecularNatural RemedyNatureNormal CellNuclearNude MiceOncogenicOxidation-ReductionOxidative StressPancreasPathologyPathway interactionsPharmaceutical PreparationsPhellodendronPhenotypePhytochemicalPreventiveProcessProductionPropertyProteinsReactive Oxygen SpeciesRegulationResistanceRoleSerumSignal TransductionSourceTestingTherapeuticTissuesToxic effectWitWorkbasecancer cellcytotoxicimplantationindium arsenideinhibition of autophagyinhibitor/antagonistinnovationmortalityneoplastic cellnovelpancreatic cancer cellspancreatic neoplasmpre-clinicalpreclinical studypreventprogramsresearch studytherapeutic developmenttranscription factortumortumor growthtumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Current therapies against pancreatic cancer (PanCA) are inadequate and limited in efficacy. Therefore there is a huge unmet need for development of novel effective compounds that selectively target tumor cells. Although natural products are well recognized as sources of drugs for various diseases including cancer, very few studies systematically explored the role of natural products for their potential preventive/therapeutic benefit in pancreatic cancer. We have discovered a natural compound called "NexrutineR" (Nx) isolated from the bark of Phellodendron amurense that inhibits pancreatic cancer cell growth and induces apoptosis and autophagy through production of reactive oxygen species (ROS). Further the observed cytotoxic effects are specific to tumor cells. Nx decreased levels and activity of two key redox-regulated transcription factors that control oncogenic signaling namely NF?B and Stat3 that results in modulation of anti-apoptotic protein FLIP. Based on these observations we postulate that Nx contains novel bioactive compounds with potent anti-pancreatic cancer activity. We will test the hypothesis that Nx and its bioactive compound works through a novel mechanism in which FLIP regulation by two redox-regulated transcription factors (Stat3 and NF?B) leads to modulation of tumor cell specific programmed cell death. This hypothesis will be addressed in following specific aims: 1: Determine the mechanism of cross talk between programmed cell death processes and Nx-induced oxidative stress ina panel of human pancreatic cancer cell lines; 2: Demonstrate that the disruption of cross talk between programmed cell death processes and oxidative stress blocks or delays tumor growth using preclinical animal models of pancreatic cancer; 3: Explore the ability of Palmatine, a bioactive component of Nx recapitulate Nx-induced biological activities using cell culture models; 4: Evaluate that the disruption of cross talk between programmed cell death processes and oxidative stress using Palmatine blocks or delays tumor growth using preclinical animal models of pancreatic cancer. Nx is a promising agent for its anti-tumorigenic activity in cancer cells wit low to no toxicity in normal cells. These studies will provide a rational basis for developing alternative and complementary medicinal strategies for targeting pancreatic cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Therapeutic potential of Palmatine in pancreatic cancer
-
批准号:9348827
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Oxidative stress and programmed death pathways: Cross talk in pancreatic cancer
-
批准号:9101968
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2012
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Oxidative stress and programmed death pathways: Cross talk in pancreatic cancer
-
批准号:8867147
-
项目类别:
-
资助金额:$36.25万
-
财政年份:2012
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Oxidative stress and programmed death pathways: Cross talk in pancreatic cancer
-
批准号:8369637
-
项目类别:
-
资助金额:$13.82万
-
财政年份:2012
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Oxidative stress and programmed death pathways: Cross talk in pancreatic cancer
-
批准号:8550765
-
项目类别:
-
资助金额:$36.25万
-
财政年份:2012
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Nexrutine Phellodendron amurense bark extract: Potential use in Pancreatic Cancer
-
批准号:8132555
-
项目类别:
-
资助金额:$18.38万
-
财政年份:2010
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Akt/CREB signaling: Target for prostate cancer
-
批准号:8391589
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Akt/CREB signaling: Target for prostate cancer
-
批准号:8196336
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Nexrutine Phellodendron amurense bark extract: Potential use in Pancreatic Cancer
-
批准号:7990108
-
项目类别:
-
资助金额:$22.28万
-
财政年份:2010
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Akt/CREB signaling: Target for prostate cancer
-
批准号:7931061
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
SIRT1 as a Resveratrol target in PTEN knockout Prostate Cancer Model
-
批准号:7661153
-
项目类别:
-
资助金额:$18.72万
-
财政年份:2009
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Eugenol & 2-methoxyestradiol: combination approach to prostate cancer prevention
-
批准号:7878865
-
项目类别:
-
资助金额:$7.43万
-
财政年份:2009
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Eugenol & 2-methoxyestradiol: combination approach to prostate cancer prevention
-
批准号:7752402
-
项目类别:
-
资助金额:$7.42万
-
财政年份:2009
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
SIRT1 as a Resveratrol target in PTEN knockout Prostate Cancer Model
-
批准号:7778383
-
项目类别:
-
资助金额:$16.34万
-
财政年份:2009
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
TARGETING FLIP FOR PROSTATE CANCER PREVENTION
-
批准号:8309387
-
项目类别:
-
资助金额:$29.89万
-
财政年份:2008
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
TARGETING FLIP FOR PROSTATE CANCER PREVENTION
-
批准号:8081766
-
项目类别:
-
资助金额:$29.89万
-
财政年份:2008
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
TARGETING FLIP FOR PROSTATE CANCER PREVENTION
-
批准号:7634428
-
项目类别:
-
资助金额:$30.79万
-
财政年份:2008
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Nexrutine, a herbal extract and prostate cancer
-
批准号:6687534
-
项目类别:
-
资助金额:$24.92万
-
财政年份:2003
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Nexrutine, a herbal extract and prostate cancer
-
批准号:7161691
-
项目类别:
-
资助金额:$10.52万
-
财政年份:2003
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
Nexrutine, a herbal extract and prostate cancer
-
批准号:6797395
-
项目类别:
-
资助金额:$14.4万
-
财政年份:2003
-
负责人:ADDANKI PRATAP KUMAR
-
依托单位:
海外基金